查詢結果分析
來源資料
相關文獻
- 高級心臟救命術藥理學新知
- 選擇性血清素再吸收抑制劑
- Pharmacoepidemiology藥物流行病學--clinical pharmacology(臨床藥理學)和epidemiology(流行病學)結合而產生的一門新學科
- 厚朴不同炮炙品之藥理學比較研究
- 離體心臟再進入節律不整的電藥理學研究
- 肝素及低分子量肝素對急性肺栓塞的治療
- 精神分裂病的藥物治療:美國的現況
- A Randomized Controlled Study of Triglycyl-Vasopressin and Vasopressin Plus Nitroglycerin in the Control of Acute Esophageal Variceal Hemorrhage
- 復甦術訓練
- 高級心臟救命術考試--一位指導老師的教學經驗分享
頁籤選單縮合
題 名 | 高級心臟救命術藥理學新知=New Advanced Cardiac Life Support Pharmacology |
---|---|
作 者 | 簡微年; | 書刊名 | 中華民國重症醫學雜誌 |
卷 期 | 3:3 2001.07[民90.07] |
頁 次 | 頁232-238 |
專 輯 | 心臟專題 |
分類號 | 415.22 |
關鍵詞 | 高級心臟救命術; 血管升壓素; 低分子量肝素; 血小板醣蛋白Ⅱb/Ⅲa拮抗劑; 藥理學; ACLS; Plalet GP Ⅱb/Ⅲa inhibitors; Low molecular weight heparins; Vasopressin; Pharmacology; |
語 文 | 中文(Chinese) |
中文摘要 | 此次藥物治療新指標的擬定,彙集各國專家依照實證醫學的準則審定文獻,將藥物治療分成不同等級。在2000年版指標中,只有標準劑量的Epinephrine被建議用於促進心跳停止病人恢復自主性循環,而Vasopressin可當作Epinephrine的替代藥物,對於治療預固性心室纖維碩動及無脈搏心室頻脈,Amiodarone有較強的實證 依據,而Lidocaine則最為不確定等級。Bretylium則因不再生產而被剔除指標外,其他抗心律不整藥物的實證依據則只是普通等級。血小板醣蛋白Ⅱb/Ⅲa拮抗劑則建議可使用於非Q波心肌梗塞及不穩定型心絞痛的病人。對同類病人使用抗凝血劑治療,低分子量Heparin亦被建議可用作為非分離性Heparin的替代藥物。如此依照實證醫學等級建議用藥,可望給與臨床工作者相當明確的指引。 |
英文摘要 | Guidelines for the advanced cardiovascular life support have been published by American Association every six to eight years since the mid-1970. Unlike previous versions the 2000 version was intended to be international and recommendations had to pass an evidence-based review. New guidelines for drug therapy were graded on the strength of the scientific evidence. In the 2000 guideline, only standard dose of epinephrine was recommended to promote the return of spontaneous circulation in patients in cardiac arrest. Vasopressin can be used as an alternative drug. In shock-refractory ventricular fibrillation and pulseless ventricular tachycardia, evidence supporting amiodarone use was stronger and lidocaine was given an indeterminate rating. Amidarone is also acceptable and useful for treatment of stable monomorphic and polymorphic ventricular tachycardia. Bretylium was deleted from the algorithm because the supply is unpredictable. The evidence supporting other antiarrhythmics is only fair. Antiplalet therapy with GPⅡb/Ⅲa inhibitors were recommended for patients with non-Q-wave MI and unstable angina. Antithrombin therapy with low molecular heparins is low also an alternative to unfractioned heparin in the same group of patients. |
本系統中英文摘要資訊取自各篇刊載內容。